SELNET Guidelines Soft Tissue Sarcoma GIST 2021.
Autores:
J.Y. Blay, N. Hindi, J. Bollard, S. Aguiar Jr. M. Angel, B. Araya, D. Bernabeu, F. Campos, C.H.S. Caro-Sanchez, B. Carvajal, R. Badilla, A. Carvajal Montoya,
S. Casavilca-Zambrano, V. Castro-Oliden, M. Chacon, M. Clara, R. Correa Genoroso, F.D. Costa, M. Cuellar, A.P. dei Tos, P. Collini, H.R. Dominguez Malagon, D. Donati, A. Dufresne, M. Eriksson, M. Farias-Loza, P. Fernandez, T. Frisoni, D.Y. Garcia-Ortega, H. Gelderblom, F. Gouin, A.M. Frezza, M.C. Gomez-Mateo, J. Haro, L. Huanca, A. Lpez-Pousa, N. Jimenez, G. Lutter, M. Karanian, H. Martinez-Said, B. Kasper, B.B. Lopes David, J. Martinez-Tlahuel, J. M. Morales Perez, S. Moura David, A.G. Nascimento, E.J. Ortiz-Cruz, C.A. Mello, S. Patel, Y. Pfluger, S. Provenzano, A. Righi, A. Rodriguez, R. Salas, A. Gronchi, E. Palmerini, K. Scotlandi, T. Soule, S. Stacchiotti, C. Valverde, F. Waisberg, T.T.G. Santos, E. Zamora Estrada, J. Martin-Broto.
Introduction:
Soft tissue sarcoma (STS) is a heterogeneous group of neoplasms, encompassing > 80 different histologic subtypes. Approximately three quarter of sarcoma arise from soft-tissue, about 15% are gastrointestinal
stromal tumours (GISTs) and bone sarcoma represent the remaining 10%. The current guidelines will focus on soft-tissue and GIST, excluding Kaposi sarcoma and non-pleomorphic rhabdomyosarcoma.
